Insmed Reports Positive 12-Month TPIP OLE Data in PAH — Sustained Efficacy, Favorable Safety
INSM sits 23% above its 52-week low of $90.39.
Summary
Insmed's 12-month OLE data for TPIP in PAH showed sustained efficacy and a favorable safety profile, supporting its potential as a best-in-class once-daily prostanoid. The Phase 3 PALM-PAH trial is now the key value driver.
Key Events · Product Development and Regulatory · INSM
-
12-Month OLE Data Positive
TPIP showed sustained improvement in 6MWD (+55.7m continued, +54.1m crossed), ~60% NT-proBNP reduction, and ~80% achieved WHO FC I/II. ~65% reached Refined Low Risk REVEAL Lite 2.0 status.
-
Favorable Safety Profile
No new safety signals through 12 months; cough rate 15.4% (mostly mild), serious TEAEs 18.7%, discontinuation rate 7.7%. Doses up to 1,280 µg were well tolerated.
-
Phase 3 PALM-PAH Enrollment Progressing
The registrational Phase 3 trial is underway, with topline results expected to be the next major catalyst for TPIP.
-
Competitive Positioning
Once-daily inhaled administration and robust efficacy could position TPIP as the prostanoid of choice, challenging Tyvaso and sotatercept in the PAH market.
Analysis · INSM · Life Sciences
The 12-month open-label extension data for Insmed's inhaled treprostinil prodrug TPIP in pulmonary arterial hypertension delivered sustained improvements across all efficacy measures alongside a clean safety profile. Patients who continued TPIP added 55.7 meters in 6-minute walk distance, while those crossing over from placebo gained 54.1 meters — both groups saw an ~60% reduction in NT-proBNP, a cardiac stress biomarker. Roughly 80% of patients reached WHO Functional Class I or II, and ~65% hit Refined Low Risk status on the REVEAL Lite 2.0 score, a threshold correlating with a three-year mortality risk below 5%. No new safety signals emerged, with cough rates low and mostly mild. These results strengthen the case for TPIP as a once-daily prostanoid that could challenge entrenched therapies like Tyvaso and sotatercept. The ongoing Phase 3 PALM-PAH trial now stands as the key catalyst, with enrollment progressing. For a $23.8B biotech, positive pipeline data reinforces the growth narrative beyond the recent BRINSUPRI launch, though the stock already reflects high expectations.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INSM was trading at $111.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.8B. The 52-week trading range was $90.39 to $212.75. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.